EHS
EHS

Ivosidenib receives FDA approval to treat acute myeloid leukemia patients with IDH1 mutation

Clinical trials at University of Colorado Cancer Center and elsewhere now result in the drug ivosidenib earning approval from the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 mutation.

Source link

EHS
Back to top button